drugset / Trial / NCT05141422

A Drug-drug Interaction Study of SHR2150 on Healthy Chinese Volunteers

NCT05141422

Phase 1 Unknown 20 enrolled Jiangsu HengRui Medicine Co., Ltd.
NaSingle-groupOpen-labelBasic science

Summary

The study is a single-centre, open-label, fixed-sequence, self-controlled clinical trial. It is planned to enroll 20 healthy adult subjects. Subjects will take SHR2150 on Day 1 and Day 21, and take efavirenz from Day 7 to Day 26.

Timeline

Start
2021-12-13
Primary completion
2022-01-15
Completion
2022-01-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Efavirenz Other / unclassified
Subject SHR2150 Small molecule